title: [IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma].
abstract: The study was aimed to evaluate the effect of IEMAD (modified MIME) composed of isofosfamide, VM26 or VP16, methotrexate, cytarabine, dexamethasone or methylprednisolone, in treatment of refractory or relapsed non-Hodgkin's lymphoma. Twenty-five patients with refractory or relapsed non-Hodgkin's lymphoma (11 refractory NHL patients, 14 relapsed NHL patients) were treated with IEMAD regimen. The results showed that the complete remission rate was 24.0% (6/25) and the partial remission rate was 28.0%, having an overall response rate of 52%. The median survival duration was 13 months and the median duration of progression-free survival was 8 months. The most frequent complications were gastrointestinal complaint (nausea, vomiting etc.) and myelosuppression. No treatment related mortality was found. It is concluded that the IEMAD (modified MIME) regimen may be a safe and effective regimen that can be used in treatment of patients with refractory or relapsed non-Hodgkin's lymphoma who did not respond to other regimens.
authors.affiliation: Department of Hematology, General Hospital of PLA, Beijing 100853, China.
authors.forename: Hong-Hua
authors.initials: HH
authors.lastname: Li
authors.forename: Xiao-Xiong
authors.initials: XX
authors.lastname: Wu
authors.forename: Quan-Shun
authors.initials: QS
authors.lastname: Wang
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhao
authors.forename: Jian
authors.initials: J
authors.lastname: Bo
authors.forename: Shu-Hong
authors.initials: SH
authors.lastname: Wang
authors.forename: Wan-Ming
authors.initials: WM
authors.lastname: DA
authors.forename: Li
authors.initials: L
authors.lastname: Yu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008935:Mitoguazone / Q000008:administration & dosage; D012008:Recurrence
chemical_list: D003561:Cytarabine; D005047:Etoposide; D003907:Dexamethasone; D008935:Mitoguazone; D007069:Ifosfamide; D008727:Methotrexate